Indirect comparison between immune checkpoint inhibitors and targeted therapies for the treatment of melanoma

Conclusions: For the unresectable late-stage melanoma, IMM may be a better choice for the combined treatment with chemotherapy. If the chemotherapy is not tolerable for patients, BRAFi involved TAR can be considered.

Source: Journal of Cancer - December 14, 2019 Category: Cancer & Oncology Authors: Minliang Wu, Yuchong Wang, Yalong Xu, Ji Zhu, Chuan Lv, Mengyan Sun, Rui Guo, Yu Xia, Wei Zhang, Chunyu Xue Tags: Research Paper Source Type: research